



Final Appraisal Recommendation

Advice number: 1322 – July 2022

Brivaracetam (Briviact®) 10 mg, 25 mg, 50 mg, 75 mg, 100 mg tablets, 10 mg/ml oral solution, 10 mg/ml solution for injection/infusion

Submission by UCB Pharma Ltd

Recommendation of the All Wales Medicines Strategy Group

Brivaracetam (Briviact®) is recommended as an option for restricted use within NHS Wales

Brivaracetam (Briviact®) should be restricted for use in the treatment of patients with refractory epilepsy, who remain uncontrolled with, or are intolerant to, other adjunctive anti-epileptic medicines, within its licensed indication as adjunctive therapy in the treatment of partial-onset seizures (POS) with or without secondary generalisation in adults, adolescents and children from 2 years of age with epilepsy.

Additional note(s):

- This advice incorporates and replaces the AWMSG recommendation for brivaracetam (Briviact®) for restricted use in the treatment of patients with refractory epilepsy, in adults, adolescents and children from 4 years of age (Advice number 2318, originally published December 2018).

In reaching the above recommendation AWMSG has taken account of the appraisal documentation prepared by the AWMSG Secretariat (reference number 4614), which includes the All Wales Toxicology and Therapeutics Centre (AWTTC) assessment form, clinical expert opinion (where available), the views of patients/patient carers (where available) and the lay member perspective.

This recommendation has been ratified by Welsh Government and will be considered for review after three years.

Statement of use: No part of this recommendation may be reproduced without the whole recommendation being quoted in full and cited as:

All Wales Medicines Strategy Group Final Appraisal Recommendation –
1322:

Brivaracetam (Briviact®) 10 mg, 25 mg, 50 mg, 75 mg, 100 mg tablets, 10 mg/ml oral solution, 10 mg/ml solution for injection/infusion July 2022